Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Average Target Price from Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $6.56.

Several research analysts recently commented on the stock. Piper Sandler dropped their target price on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Craig Hallum decreased their target price on Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Morgan Stanley downgraded Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $4.00 to $3.00 in a research report on Tuesday, August 6th. BTIG Research cut Akoya Biosciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered shares of Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th.

Akoya Biosciences Trading Down 0.9 %

Akoya Biosciences stock opened at $3.19 on Friday. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company’s fifty day moving average price is $2.86 and its two-hundred day moving average price is $2.65. The company has a market capitalization of $157.91 million, a price-to-earnings ratio of -2.59 and a beta of 1.34. The company has a debt-to-equity ratio of 3.43, a current ratio of 2.73 and a quick ratio of 1.98.

Institutional Investors Weigh In On Akoya Biosciences

Large investors have recently bought and sold shares of the business. Silvercrest Asset Management Group LLC bought a new stake in Akoya Biosciences during the 1st quarter worth about $2,724,000. Vanguard Group Inc. grew its stake in shares of Akoya Biosciences by 3.3% during the first quarter. Vanguard Group Inc. now owns 1,454,288 shares of the company’s stock valued at $6,821,000 after purchasing an additional 46,131 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Akoya Biosciences by 16.2% in the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares in the last quarter. Regal Investment Advisors LLC raised its position in Akoya Biosciences by 64.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after buying an additional 144,903 shares in the last quarter. 79.42% of the stock is currently owned by institutional investors.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.